| AHA1 (AHSA1; activator of Hsp90 ATPase 1) is a conserved co‑chaperone that binds the molecular chaperone Hsp90 and functions as the most potent endogenous accelerator of its ATPase activity, thereby modulating the kinetics and outcome of Hsp90‑dependent client protein folding, stabilization, and maturation across many cellular pathways. The protein is organized into an N‑terminal domain that docks onto the middle domain of Hsp90 and a C‑terminal domain that contacts the N‑terminal ATPase domain, and this bipartite engagement promotes a conformational switch in Hsp90 that enhances ATP binding, accelerates ATP hydrolysis, and stabilizes the closed, catalytically competent state of the chaperone cycle. By stimulating Hsp90 ATPase activity, AHA1 shortens the dwell time of client proteins within specific chaperone states and shifts the balance between Hsp90 complexes that include other co‑chaperones such as p23, Hop, and Cdc37, which positions AHA1 as a key determinant of how Hsp90 handles kinases, transcription factors, and other signaling proteins involved in cell proliferation, survival, and differentiation. AHA1 associates with large Hsp90-centered heteroprotein assemblies that contain multiple clients and regulatory factors, and its expression level influences the maturation and stability of oncogenic clients including tyrosine kinases, steroid hormone receptors, and cell-cycle regulators, linking elevated AHA1 activity to enhanced prosurvival signaling and therapy resistance in several tumor types. In neuronal systems, AHA1 contributes to the handling of aggregation-prone proteins such as tau and huntingtin by modulating Hsp90’s chaperone and degradation decisions, and altered AHA1 abundance or activity is reported in models of Alzheimer’s, Huntington’s disease, and other proteinopathy-linked neurodegenerative conditions where proteostasis is impaired. AHA1 can bind stress-denatured proteins directly and delay their aggregation in the absence of Hsp90, indicating autonomous chaperone activity that broadens its impact on cellular protein quality control under stress. AHA1 also participates in the biogenesis and function of Dicer1 and thereby influences microRNA maturation, adding a layer of post-transcriptional gene regulation to its effects on chaperone-dependent proteomes and connecting AHA1 to pathways that govern cell identity, oncogenic transformation, and neuronal resilience. Dysregulated AHA1 expression in cancer and neurodegeneration correlates with disrupted client handling and disease progression, and small-molecule disruptors of the Hsp90–AHA1 interaction or inhibitors of AHA1 function show efficacy in experimental models by rebalancing Hsp90 client networks. |
